The worldwide demand for erythropoietin drugs also referred as hematopoietic drugs is expected to remain strong in the forthcoming years.

Erythropoietin Drugs Market, by Drug Class, Revenue (US$ Mn) 2015-2025

Erythropoietin on a tightrope: Balancing neuronal and vascular protection between intrinsic and extrinsic pathways.

A global strategy for prevention and detection of blood doping with erythropoietin and related drugs.

Furthermore, erythropoietin levels were measured at admission, 24 and 72 hours following admission, and on day 7.

Recombinant human erythropoietin upregulated the expression of vascular endothelial growth factor through phosphatidylinositol 3 kinase/Akt pathway

Polycythemia vera is diagnosed according to WHO criteria including JAK2V617F mutation, serum erythropoietin levels and bone marrow biopsy.

In this report, Technavio covers the market outlook and growth prospects of the global erythropoietin drugs market for 2017-2021.

- EPO drugs market is witnessing high commercialization of biosimilars for the 'off-patent' drug namely Erythropoietin alfa.

Erythropoietin (EPO) has been well characterized as a renal glycoprotein hormone regulating red blood cell production by inhibiting apoptosis of erythrocyte progenitors in hematopoietic tissues (1).

Erythropoiesis, the formation of red blood cells from multipotent stem cells in the bone marrow, is an exquisitely regulated process in which the glycoprotein hormone erythropoietin (EPO), which is primarily produced in either adult kidney or fetal liver [1], plays a role [2] as the major humoral regulator of red cell production [3].

Erythropoietin (EPO) is a hemopoietic hormone, which controls erythropoiesis, produced by the renal interstitium in response to hypoxia (1).

In an anemia management subanalysis of a study comparing sustained virologic response (SVR) rates in cirrhotic and noncirrhotic patients treated with boceprevir (Victrelis), pegylated interferon alfa-2b (Peg-Intron), and ribavirin (RBV), 57% of patients with cirrhosis and anemia treated with a ribavirin dose reduction had an SVR, compared with 64% of those treated with erythropoietin. Among noncirrhotic patients with anemia, the respective SVR rates were 73% and 72%; none of the differences was significant, Dr.